| Symbol |
CR1 |
| Full Name |
Complement Component 1q Receptor |
| Alternative Names |
CD35, C3b/C4b Receptor, Immune Adherence Receptor |
| Chromosome |
1q32.2 |
| NCBI Gene |
1378 |
| Ensembl |
ENSG00000203797 |
| OMIM |
120600 |
| UniProt |
P08578 |
| Protein Length |
1998 amino acids (long isoform), 549 amino acids (short isoform) |
| Molecular Weight |
~220 kDa (long), ~60 kDa (short) |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers-disease), [Systemic Lupus Erythematosus](/diseases/systemic-lupus-erythematosus), [Multiple Sclerosis](/diseases/multiple-sclerosis), Age-related Macular Degeneration |
| Expression |
Blood cells (erythrocytes, leukocytes), Brain (microglia, astrocytes), Kidney, Spleen |
rs6656401 (intron, risk)
rs3818362 (intron, risk)
rs1205 (3' UTR, expression) |
CR1 (Complement Component 1q Receptor, also known as CD35 or C3b/C4b Receptor) is a gene located on chromosome 1q32.2 that encodes a large transmembrane glycoprotein serving as a receptor for complement system proteins. CR1 was first identified as a significant genetic risk factor for late-onset Alzheimer's disease (AD) in the landmark genome-wide association study (GWAS) published in 2009, alongside CLU and PICALM . This discovery highlighted the importance of complement-mediated neuroinflammation in AD pathogenesis and opened new avenues for therapeutic intervention.
CR1 is one of the most polymorphic genes in the human genome, with extensive variation in both coding and non-coding regions that influence disease susceptibility. The protein is expressed on various immune cells and glial cells in the brain, where it plays critical roles in immune complex clearance, complement regulation, synaptic pruning, and amyloid-beta clearance.
¶ Gene Structure and Organization
¶ Genomic Location and Architecture
The CR1 gene is positioned on chromosome 1q32.2, a region of significant medical relevance due to its involvement in multiple immune-mediated diseases. The gene spans approximately 45 kb of genomic DNA and consists of 38 exons encoding a large protein with multiple functional domains.
Chromosomal Position (GRCh38):
- Location: 1q32.2 (coordinates: chr1:207,691,048-207,737,000)
- Orientation: Sense strand
- Gene size: ~45 kb
CR1 shows interesting evolutionary conservation patterns:
- Primates: High conservation with multiple isoforms
- Rodents: Single ortholog (Cr1) with different domain structure
- Lower vertebrates: Related complement receptors with simplified structure
The expansion of SCR domains in primate CR1 suggests adaptive evolution possibly related to immune surveillance functions.
¶ Domain Architecture
CR1 is a multi-domain glycoprotein with distinctive structural features:
Primary Isoform (Long):
- Signal peptide — Enables cotranslational insertion into the membrane
- N-terminal leader sequence — Contains the ligand-binding region
- Short Consensus Repeat (SCR) domains — 30 tandem SCRs, also called complement control protein modules (CCPs)
- Transmembrane region — Single-pass alpha-helical transmembrane domain
- Cytoplasmic tail — Contains signaling motifs including phosphorylation sites
SCR Domain Structure:
Each SCR domain consists of approximately 60 amino acids arranged in a β-sheet fold with conserved disulfide bonds. These domains mediate binding to:
- C3b (opsonin)
- C4b (opsonin)
- Immune complexes
- Complement proteins
CR1 produces multiple isoforms through alternative splicing:
| Isoform |
Length |
Expression |
Function |
| CR1-F (Long) |
1998 aa |
Erythrocytes, leukocytes, brain |
Primary isoform |
| CR1-S (Short) |
549 aa |
Alternative splicing |
Soluble form possible |
| CR1-Duplicate |
Variable |
Some populations |
Gene duplication |
The long isoform (CR1-F) is the predominant form expressed on cell surfaces, while alternative splicing can produce truncated variants with modified function .
CR1's most well-characterized function is in the clearance of immune complexes:
Mechanism:
- Immune complex binding — C3b/C4b-coated complexes bind to CR1 on erythrocytes
- Transport to spleen — Erythrocytes carry complexes to splenic macrophages
- Transfer and phagocytosis — Complexes are transferred to splenic macrophages for degradation
- Erythrocyte return — Erythrocytes return to circulation
This system clears approximately 50% of circulating immune complexes and is critical for preventing immune complex deposition in tissues.
CR1 serves as a cofactor for complement factor I-mediated cleavage of C3b and C4b:
- Factor I cofactor activity — CR1 accelerates factor I-mediated proteolysis of C3b
- Decay-accelerating activity — Accelerates decay of C3 convertases
- Regulation of complement cascade — Prevents excessive complement activation
On Erythrocytes:
- Primary immune adherence receptor
- Clearance of opsonized pathogens
- Transport function for immune complexes
On Leukocytes:
- Modulates phagocyte activation
- Regulates inflammatory responses
- Affects cell adhesion and migration
CR1 is expressed on multiple cell types within the brain:
Glial Expression:
- Microglia — Primary source of CR1 in the brain, highly expressed on both resting and activated microglia
- Astrocytes — Moderate expression, upregulated in reactive astrocytes
- Oligodendrocytes — Lower expression, possible role in myelin maintenance
Neuronal Expression:
- Limited expression in neurons under normal conditions
- Upregulation in AD and other neurodegenerative conditions
Recent research demonstrates that CR1 expression is significantly altered in AD brains:
- Increased mRNA levels — CR1 transcript levels elevated in AD frontal cortex and hippocampus
- Increased protein expression — CR1 protein co-localizes with microglia and astrocytes in AD brains
- Glial localization — CR1 detected primarily on microglia and astrocytes surrounding amyloid plaques
The long variant of CR1 has been specifically associated with AD risk through effects on glial function .
¶ Genetic Architecture and AD Risk
CR1 was identified as an AD risk gene in the seminal 2009 GWAS meta-analysis:
- Discovery: Lambert et al. 2009, Nature Genetics
- Replication: Naj et al. 2011, Nature Genetics
- Effect size: Odds ratio ~1.15-1.20 per risk allele
| Variant |
Location |
Risk Allele |
Odds Ratio |
Function |
| rs6656401 |
Intron 10 |
A |
~1.15 |
Regulatory |
| rs3818362 |
Intron 26 |
C |
~1.13 |
Regulatory |
| rs1205 |
3' UTR |
G |
~1.10 |
Expression (eQTL) |
- European ancestry: rs6656401-A frequency ~19%
- East Asian ancestry: Different LD patterns
- African ancestry: Higher frequency of protective haplotypes
GWAS variants influence AD risk through multiple mechanisms:
- Expression regulation — eQTL effects alter CR1 expression levels in brain tissue
- Alternative splicing — Some variants may affect isoform ratios
- Regulatory element function — Variants in enhancers may modify cell-type specific expression
CR1's association with AD represents one of the clearest links between complement genetics and neurodegeneration:
Pathogenic Mechanisms:
-
Complement-Mediated Neuroinflammation
- CR1 variants affect C1q binding and downstream complement activation
- Altered neuroinflammatory responses in carriers of risk variants
- The complement cascade is now recognized as a "key driver of pathological neuroinflammation" in AD
-
Amyloid Clearance
- CR1 participates in complement-dependent phagocytosis of amyloid-beta plaques
- Impaired clearance in carriers of risk variants
- Co-localization of CR1 with amyloid plaques in AD brains
-
Synaptic Pruning
- CR1 mediates complement-dependent synaptic elimination during development
- Dysregulated pruning may contribute to synaptic loss in AD
- C1q binding to synapses is enhanced in AD brains
-
Tau Pathology Connection
- Interaction between complement activation and tau pathology
- Microglial CR1 expression correlates with tau burden
Complement C1q in AD:
Recent studies have demonstrated widespread C1q binding in AD brains, with C1q colocalizing with synapses and contributing to synaptic loss .
CR1 deficiency is classically associated with SLE:
- Reduced erythrocyte CR1 — Downregulation of CR1 on erythrocytes in SLE patients
- Impaired immune complex clearance — Contributes to tissue deposition
- Autoimmune manifestations — Linked to disease severity
- Genetic association — CR1 variants modify SLE susceptibility
CR1 is implicated in demyelinating diseases:
- Complement-mediated demyelination — CR1 regulates complement activation in CNS
- Genetic association — CR1 variants modify MS risk
- Therapeutic implications — Complement modulation is being explored as treatment
Age-Related Macular Degeneration (AMD):
- CR1 variants associated with AMD risk
- Shared genetic architecture with AD
Malaria Susceptibility:
- CR1 serves as receptor for Plasmodium falciparum erythrocyte membrane protein 1 (EMP1)
- Variants affect malaria severity
The complement system is a critical driver of neuroinflammation in AD:
Classical Pathway Activation:
C1q → C1r → C1s → C4 → C2 → C3 convertase (C4b2a)
↓
C3 convertase
↓
C3a (inflammatory) + C3b (opsonization)
↓
C5 convertase
↓
C5a (chemoattractant) + C5b → MAC
CR1 modulates this cascade at multiple points:
- Serving as cofactor for factor I (inactivates C3b/C4b)
- Accelerating decay of C3/C5 convertases
- Clearing complement-coated debris
CR1 contributes to amyloid clearance through:
- Complement-dependent phagocytosis — C3b-coated Aβ recognized by CR1
- Microglial activation — CR1 signaling modulates microglial phagocytosis
- Transport to peripheral circulation — Possible role in Aβ efflux from brain
The complement-CR1 axis affects synapses through:
- Developmental pruning — CR1 mediates C1q-dependent synapse elimination
- Pathological pruning — Enhanced complement activation in AD leads to excessive synapse loss
- Synaptic protection — Therapeutic modulation of complement may protect synapses
CR1 represents a promising target for AD therapeutic development:
| Approach |
Target |
Status |
Notes |
| CR1 agonists |
Enhance clearance |
Preclinical |
Increase CR1-mediated phagocytosis |
| C1q inhibitors |
Block complement activation |
Clinical trials |
Prevent pathological pruning |
| Complement blockers |
Downstream targets |
Various |
Anti-C3, anti-C5 therapies |
| Gene therapy |
Modulate CR1 expression |
Discovery |
AAV delivery approaches |
¶ Clinical Trial Landscape
Multiple complement-targeting approaches are in development:
- Anti-C1q antibodies — In clinical trials for AD
- Small molecule complement inhibitors — Various compounds in development
- CR1-based approaches — Preclinical validation ongoing
CR1 has potential as a biomarker:
- Plasma CR1 levels — Correlate with disease status
- Genetic stratification — CR1 variants for risk assessment
- Therapeutic monitoring — CR1 expression as treatment response marker
CR1 interacts with several other AD risk genes:
| Gene |
Interaction |
Pathway |
| CLU |
Same GWAS hit |
Complement regulation |
| PICALM |
Endocytic pathway |
Endosomal trafficking |
| TREM2 |
Microglial function |
Phagocytosis |
| CD33 |
Immune receptors |
Sialic acid signaling |
| MS4A6A |
Cell surface signaling |
Immune modulation |
This network of immune-related genes points to neuroinflammation as a central mechanism in AD pathogenesis.
CR1 is highly expressed on microglia and exhibits disease-specific patterns:
- Homeostatic Microglia — Low CR1 expression in resting state
- Disease-Associated Microglia (DAM) — Upregulated in DAM phenotype
- Aging Effects — Age-related increase in microglial CR1
- Regional Variation — Differential expression across brain regions
- Sexual Dimorphism — Sex-specific expression patterns
¶ CR1 and Microglial Phagocytosis
CR1 modulates microglial phagocytic activity:
- Opsonin Recognition — CR1 recognizes C3b-coated targets
- Phagocytic Efficiency — CR1 levels correlate with phagocytic capacity
- Clearance Defects — CR1 dysfunction impairs debris clearance
- Synaptic Pruning — CR1 mediates developmental synapse elimination
- Pathological Overactivation — Excessive pruning in AD
CR1 engages multiple signaling pathways:
- Syk Kinase Activation — Downstream signaling cascades
- PI3K/Akt Pathway — Cell survival and proliferation
- MAPK Pathways — Inflammatory responses
- NF-κB Modulation — Cytokine production
- STAT Signaling — Gene expression regulation
¶ CR1 and the Blood-Brain Barrier
CR1 plays a role in blood-brain barrier function:
- Endothelial CR1 — Expression on brain endothelial cells
- Pericyte Interactions — Modulates pericyte function
- BBB Integrity — Maintains tight junction proteins
- Transcytosis — Regulates receptor-mediated transport
- Leukocyte Trafficking — Controls immune cell entry
CR1 facilitates cross-talk between periphery and brain:
- Immune Complex Clearance — Prevents peripheral inflammation from affecting CNS
- Cytokine Signaling — Modulates peripheral cytokine effects
- Aβ Drainage — Peripheral sink for brain-derived Aβ
- Transport Functions — Regulates molecule passage
- Systemic Inflammation — Alters CNS responses to peripheral signals
The complement system interacts with tau pathology:
- C1q Binding — C1q directly binds to tau aggregates
- Opsonization — Tau oligomers opsonized by complement
- Microglial Clearance — CR1-mediated uptake of tau
- Propagation — Complement may facilitate tau spread
- Seeding — Complement-coated tau more infectious
Targeting complement-tau interactions:
- C1q Blockade — Prevents tau-induced complement activation
- CR1 Agonists — Enhance tau clearance
- Combination Therapy — Anti-tau + complement inhibitors
- Biomarker Development — Complement-tau as progression markers
- Clinical Trials — Complement modulators in tauopathies
¶ CR1 Genetic Variation and Functional Consequences
Alternative splicing affects CR1 function:
- Exon Skipping — Produces truncated isoforms
- Intron Retention — Alters protein coding
- Promoter Usage — Different tissue-specific promoters
- Isoform Ratios — Disease-associated shifts in isoforms
- Functional Consequences — Altered ligand binding
CR1 exhibits copy number variation:
- Gene Duplication — Common in African populations
- Deletions — Associated with autoimmunity
- Expression Effects — CNV correlates with expression
- Disease Associations — Modified AD risk
- Evolutionary Context — Positive selection signals
Genetic variants affect CR1 expression:
- Brain eQTLs — Tissue-specific expression effects
- Blood eQTLs — Peripheral expression changes
- Cell Type Effects — Microglia-specific eQTLs
- Dynamic Expression — Disease state eQTLs
- Therapeutic Targeting — eQTL-informed drug development
CR1 effects span disease stages:
- Preclinical AD — Early expression changes
- MCI Stage — Progressive alterations
- Moderate AD — Peak dysregulation
- Severe AD — Advanced changes
- Biomarker Utility — Stage-specific markers
CR1 implications extend beyond AD:
- Vascular Dementia — Shared vascular mechanisms
- Lewy Body Dementia — Complement involvement
- Frontotemporal Dementia — Less characterized
- Parkinson's Disease — Possible overlaps
- Mixed Dementia — Combined pathology effects
Comparative analysis reveals:
- Common Mechanisms — Shared inflammatory pathways
- Disease-Specific Effects — Unique signatures
- Biomarker Overlap — Non-specific markers
- Therapeutic Implications — Broad complement targeting
- Research Gaps — Areas needing study
¶ CR1 and Aging
CR1 expression alters with aging:
- Increased Expression — Age-related upregulation
- Cellular Distribution — Shift in cell type expression
- Functional Consequences — Altered clearance capacity
- Inflammaging — Contributions to age-related inflammation
- Interaction with AD — Age as disease modifier
CR1 in cellular senescence:
- Senescent Microglia — Increased CR1 in senescent cells
- SASP Regulation — Compartment involvement in SASP
- Immune Surveillance — Clearance of senescent cells
- Therapeutic Implications — Senolytic targeting
- Age-Related Diseases — Broader implications
Research models for CR1 study:
- iPSC-Derived Microglia — Human microglial models
- Primary Cultures — Neuron-glia co-cultures
- Organoid Systems — Brain organoid applications
- Transwell Cultures — BBB modeling
- CRISPR Models — Genetic manipulation
Animal models for CR1 research:
- Mouse Cr1 Orthologs — Different domain structure
- Transgenic Models — Human CR1 expression
- Knockout Studies — Functional validation
- APP/PS1 Crosses — Disease model combinations
- Aging Studies — Age-related changes
Cross-species comparisons:
- Primate Conservation — High similarity to human
- Rodent Differences — Structural variations
- Evolutionary Implications — Immune system expansion
- Model Limitations — Species-specific considerations
- Translation Potential — Preclinical to clinical bridge
Single-cell technologies reveal:
- Cell-Type Specificity — Discrete microglial subsets
- Trajectory Analysis — Developmental progressions
- Spatial Transcriptomics — Regional heterogeneity
- Cell-Cell Interactions — Communication networks
- Clonal Analysis — Lineage relationships
Integrative approaches:
- Genomics — GWAS follow-up
- Transcriptomics — Expression patterns
- Proteomics — Protein levels
- Metabolomics — Metabolic effects
- Epigenomics — Regulatory changes
Preventive strategies:
- Lifestyle Modifications — Exercise, diet effects
- Early Intervention — Preclinical targeting
- Risk Reduction — Genetic risk mitigation
- Biomarker Monitoring — Early detection
- Public Health Implications — Population-level strategies
¶ Research Priorities and Knowledge Gaps
Key knowledge gaps remain:
- Mechanistic Details — Exact pathogenic mechanisms
- Cell Type Specificity — Microglial vs. neuronal CR1
- Peripheral vs. CNS — Relative contributions
- Therapeutic Targeting — Optimal intervention points
- Biomarker Validation — Clinical utility assessment
Priority areas for future research:
- Functional Studies — Variant validation
- Therapeutic Development — Drug discovery
- Biomarker Studies — Clinical validation
- Model Development — Improved model systems
- Clinical Translation — Human studies
- Cr1 knockout mice — Viable with immune complex clearance defects
- Conditional knockouts — Brain-specific deletion models
- APP/PS1 crosses — Show exacerbated complement activation
- iPSC-derived microglia — Human model systems
- Primary neuron-glia cultures — Mechanism studies
- Organotypic brain slices — Developmental studies
- Functional validation of GWAS-identified variants
- Mechanistic studies of CR1 in complement biology
- Therapeutic targeting of complement pathways
- Biomarker development using CR1 expression
- Single-cell analysis of CR1-expressing cell types
- How do CR1 variants specifically affect glial function?
- What is the relative importance of peripheral vs. central CR1?
- Can complement modulation prevent synaptic loss in AD?